Lidocaine plus Dexmedetomidine

PreclinicalSmall molecule

Lidocaine plus Dexmedetomidine is one of 3 small molecule programs targeting Lidocaine Infusion. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lidocaine InfusionCompleted

Lidocaine InfusionPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Lidocaine Infusion

#DrugCompanyPhaseTrials

IV Lidocaine

WWake Forest University Health Sciences

Phase 3

1 2

Lidocaine %2 Ampoule

YYAARA TABIB

Preclinical

1 3

Lidocaine plus Dexmedetomidine

AAnqing Municipal Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lidocaine Infusion1 trial

Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines

Completed·—·N/A·NCT03276533·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lidocaine plus Dexmedetomidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lidocaine plus Dexmedetomidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lidocaine plus Dexmedetomidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anqing Municipal Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAnqing Municipal Hospital

Lidocaine plus Dexmedetomidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lidocaine Infusion1 trial

References

Drug Info

Quick Facts

Related News